Cannabis Science, Inc. (CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting is intent on putting together a whos who advisory board to compete with big players in the sector such as GW Pharmaceuticals Plc, (GWPH:NASDAQ), MEDBOX INC, (MDBX:OTC.QB),NUVILEX (NVLX:OTC.QB)
COLORADO SPRINGS, Colo. / ACCESSWIRE / July 24th, 2014 / Cannabis Science, Inc. (OTCQB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting is pleased to announce the appointment of Dr. Roscoe M. Moore, Jr., formerly the US Assistant Surgeon General, for a second term on the scientific advisory board and as a special Senior Advisor to the Company. Among other contributions, Dr. Moore will be leading the Cannabis Science initiative in Africa.
"We are delighted that Dr. Moore has agreed to continue to share his breadth of knowledge and experience with Cannabis Science executives and scientific advisors on epidemiology, government regulation, and international challenges in delivery of disease treatment”, stated Dorothy H. Bray, Ph.D., Director, President and CEO, Cannabis Science, Inc.
About Roscoe M. Moore Jr., D.V.M., M.P.H., Ph.D., Senior Advisor to Cannabis Science and Senior Member of the Company's Scientific Advisory Board
Dr. Moore brings to the Company substantial experience and leadership through his government service that includes responsibilities as former Assistant United States Surgeon General and Rear Admiral in the USPHS.
Dr. Moore served as the chief epidemiologist with the Centers of Devices and Radiological Health in the US Food and Drug Administration (FDA), along with the positions he held in the US Public Health Service (USPHS), and most recently, with the Office of the US Secretary of Health and Human Services (HHS).
Dr. Moore was named a Senior Fellow at the Potomac Institute in June 2003. He is currently the CEO and Vice Chairman of the Global Flu Consortium.
Dr. Moore was the top-ranking veterinarian in all of the Uniformed Services, and served as the Associate Director for Development Support and African Affairs for HHS. In this capacity, Dr. Moore was the principal liaison between HHS and ministries of health for 53 countries in Africa. He also held positions at the National Institutes of Health (NIH), the Centers for Disease Control (CDC).
Dr. Moore has a Ph.D. in Epidemiology from The Johns Hopkins University, an M.P.H. in Epidemiology from the University of Michigan, a Doctor of Veterinary Medicine and a B.S. degree from Tuskegee Institute; and an honorary D.Sc. degree from Tuskegee University in recognition of his distinguished public health career. He has written or co-authored over 100 publications covering a broad range of public health issues. For a full biography of Dr. Moore, please see http://phrockwood.com/adobePDFs/Biography.pdf.
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment of illnesses caused by infections as well as for age-related ailments. The Company's initial focus is on skin cancers and neurological conditions.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science, Inc.
Dr. Dorothy Bray, Director, President & CEO
Robert Kane, Director & CFO